67 related articles for article (PubMed ID: 7835800)
1. Population distribution of lifetime risk of ovarian cancer in the United States.
Pearce CL; Stram DO; Ness RB; Stram DA; Roman LD; Templeman C; Lee AW; Menon U; Fasching PA; McAlpine JN; Doherty JA; Modugno F; Schildkraut JM; Rossing MA; Huntsman DG; Wu AH; Berchuck A; Pike MC; Pharoah PDP
Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):671-676. PubMed ID: 25623732
[TBL] [Abstract][Full Text] [Related]
2. The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
Cabasag CJ; Arnold M; Butler J; Inoue M; Trabert B; Webb PM; Bray F; Soerjomataram I
Int J Cancer; 2020 Feb; 146(3):749-758. PubMed ID: 30968402
[TBL] [Abstract][Full Text] [Related]
3. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study.
Li K; Hüsing A; Fortner RT; Tjønneland A; Hansen L; Dossus L; Chang-Claude J; Bergmann M; Steffen A; Bamia C; Trichopoulos D; Trichopoulou A; Palli D; Mattiello A; Agnoli C; Tumino R; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HB; Gram IT; Weiderpass E; Sánchez-Cantalejo E; Chirlaque MD; Duell EJ; Ardanaz E; Idahl A; Lundin E; Khaw KT; Travis RC; Merritt MA; Gunter MJ; Riboli E; Ferrari P; Terry K; Cramer D; Kaaks R
Br J Cancer; 2015 Mar; 112(7):1257-65. PubMed ID: 25742479
[TBL] [Abstract][Full Text] [Related]
4. Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond.
Rein HL; Bernstein KA
DNA Repair (Amst); 2023 Oct; 130():103563. PubMed ID: 37651978
[TBL] [Abstract][Full Text] [Related]
5. Expression of Cyclooxygenase-1 and 2 in Epithelial Ovarian Cancer: A Clinicopathologic Study.
Khunnarong J; Tangjitgamol S; Manusirivithaya S; Pataradool K; Thavaramara T; Leelahakorn S
World J Oncol; 2010 Feb; 1(1):19-27. PubMed ID: 29147175
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.
Zucha MA; Wu AT; Lee WH; Wang LS; Lin WW; Yuan CC; Yeh CT
Oncotarget; 2015 May; 6(15):13255-68. PubMed ID: 26036311
[TBL] [Abstract][Full Text] [Related]
7. Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
Belotte J; Fletcher NM; Alexis M; Morris RT; Munkarah AR; Diamond MP; Saed GM
Reprod Sci; 2015 Jan; 22(1):38-46. PubMed ID: 25038052
[TBL] [Abstract][Full Text] [Related]
8. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide.
Serpe L; Gallicchio M; Canaparo R; Dosio F
Pharmgenomics Pers Med; 2014; 7():31-42. PubMed ID: 24516337
[TBL] [Abstract][Full Text] [Related]
9. Nodal status--its impact on prognosis in advanced ovarian cancer.
Bachmann C; Bachmann S; Fehm T; Staebler A; Becker S; Rothmund R; Gardanis C; Grischke EM; Wallwiener D; Solomayer EF
J Cancer Res Clin Oncol; 2012 Feb; 138(2):261-7. PubMed ID: 22105899
[TBL] [Abstract][Full Text] [Related]
10. Potential markers for detection and monitoring of ovarian cancer.
Rein BJ; Gupta S; Dada R; Safi J; Michener C; Agarwal A
J Oncol; 2011; 2011():475983. PubMed ID: 21577260
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in the diagnosis and treatment of ovarian cancer.
Jelovac D; Armstrong DK
CA Cancer J Clin; 2011; 61(3):183-203. PubMed ID: 21521830
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".
Johnatty SE; Beesley J; Chen X; Macgregor S; Duffy DL; Spurdle AB; deFazio A; Gava N; Webb PM; Rossing MA; Doherty JA; Goodman MT; Lurie G; Thompson PJ; Wilkens LR; Ness RB; Moysich KB; Chang-Claude J; Wang-Gohrke S; Cramer DW; Terry KL; Hankinson SE; Tworoger SS; Garcia-Closas M; Yang H; Lissowska J; Chanock SJ; Pharoah PD; Song H; Whitemore AS; Pearce CL; Stram DO; Wu AH; Pike MC; Gayther SA; Ramus SJ; Menon U; Gentry-Maharaj A; Anton-Culver H; Ziogas A; Hogdall E; Kjaer SK; Hogdall C; Berchuck A; Schildkraut JM; Iversen ES; Moorman PG; Phelan CM; Sellers TA; Cunningham JM; Vierkant RA; Rider DN; Goode EL; Haviv I; Chenevix-Trench G; ; ;
PLoS Genet; 2010 Jul; 6(7):e1001016. PubMed ID: 20628624
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.
Johnatty SE; Beesley J; Chen X; Spurdle AB; Defazio A; Webb PM; ; ; Goode EL; Rider DN; Vierkant RA; Anderson S; Wu AH; Pike M; Van Den Berg D; Moysich K; Ness R; Doherty J; Rossing MA; Pearce CL; Chenevix-Trench G
Twin Res Hum Genet; 2009 Jun; 12(3):269-75. PubMed ID: 19456219
[TBL] [Abstract][Full Text] [Related]
14. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
Pal T; Permuth-Wey J; Sellers TA
Cancer; 2008 Aug; 113(4):733-42. PubMed ID: 18543306
[TBL] [Abstract][Full Text] [Related]
15. A possible link between the pubertal growth of girls and ovarian cancer in their daughters.
Barker DJ; Osmond C; Thornburg KL; Kajantie E; Eriksson JG
Am J Hum Biol; 2008; 20(6):659-62. PubMed ID: 18461601
[TBL] [Abstract][Full Text] [Related]
16. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.
Schouten LJ; Rivera C; Hunter DJ; Spiegelman D; Adami HO; Arslan A; Beeson WL; van den Brandt PA; Buring JE; Folsom AR; Fraser GE; Freudenheim JL; Goldbohm RA; Hankinson SE; Lacey JV; Leitzmann M; Lukanova A; Marshall JR; Miller AB; Patel AV; Rodriguez C; Rohan TE; Ross JA; Wolk A; Zhang SM; Smith-Warner SA
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):902-12. PubMed ID: 18381473
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in BRCA2 carriers with ovarian cancer.
Pal T; Permuth-Wey J; Kapoor R; Cantor A; Sutphen R
Fam Cancer; 2007; 6(1):113-9. PubMed ID: 17160431
[TBL] [Abstract][Full Text] [Related]
18. Characteristics relating to ovarian cancer risk: implications for prevention and detection.
Whittemore AS
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S15-9. PubMed ID: 7835800
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
